Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient with Multiple Endocrine Neoplasia 2B

Narayanan, VK, Ronghe, M, MacGregor, FB, Bradshaw, N, Davidson, R, Welbury, R orcid iconORCID: 0000-0002-9322-2440, Reed, N and Shaikh, MG (2016) Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient with Multiple Endocrine Neoplasia 2B. Journal of Pediatric Hematology/Oncology, 38 (2). pp. 155-157. ISSN 1077-4114

Full text not available from this repository.

Official URL: http://dx.doi.org/10.1097/MPH.0000000000000432

Abstract

We describe a child with advanced, metastatic, inoperable medullary carcinoma of thyroid associated with multiple endocrine neoplasia 2B and rearranged during transfection mutation with a positive response to vandetanib treatment. He responded well with a fall in calcitonin levels and a reduction in size of the thyroid malignancy, lymph nodes, and pulmonary metastases. He has been on vandetanib for 4 years with good clinical and biochemical response. Vandetanib has a role in the treatment of patients including children with inoperable locally advanced and metastatic medullary carcinoma of thyroid. More information is needed on its use in children and long-term outcome.


Repository Staff Only: item control page